Extending Therapy Options in Treating Lipid DisordersA Clinical Review of Cerivastatin, a Novel HMG-CoA Reductase Inhibitor

被引：0
|
作者：
Evan A. Stein
机构：
[1] Medical Research Laboratories,
来源：
Drugs | 1998年 / 56卷
关键词：
Adis International Limited; Pravastatin; Lovastatin; Fluvastatin; Cerivastatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cerivastatin is a third generation pure enantiomeric HMG-CoA reductase inhibitor. It reduces low density lipoprotein (LDL)-cholesterol by 22 to 44% at doses of 0.1 to 0.8 mg/day The drug has been extensively evaluated for more than 5 years in clinical trials and is currently marketed in a number of countries at doses of 0.1 to 0.3 mg/day.
引用
收藏
页码：25 / 31
页数：6
相关论文
共 50 条
  • [21] Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin
    Lettieri, J
    Krol, G
    Mazzu, A
    Fiebach, MZ
    Heller, AH
    ATHEROSCLEROSIS, 1997, 130 : 109 - 109
  • [22] Cerivastatin, a new potent HMG-CoA reductase inhibitor: Efficacy and tolerability in primary hypercholesterolemia
    Insull, W
    Stein, E
    Whalen, E
    Ripa, S
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (02) : 92192 - 92192
  • [23] The HMG-CoA reductase inhibitor cerivastatin induces an enhanced NO release from endothelial cells
    Berkels, R
    Nouri, SK
    Bartels, H
    Rösen, R
    Klaus, W
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 363 (04) : R42 - R42
  • [24] HMG-COA REDUCTASE INHIBITOR USE IN THE AGED - A REVIEW OF CLINICAL-EXPERIENCE
    LINTOTT, CJ
    SCOTT, RS
    DRUGS & AGING, 1992, 2 (06) : 518 - 529
  • [25] Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers
    Mazzu, A
    Lettieri, J
    Kaiser, L
    Mullican, W
    Heller, AH
    JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (08): : 715 - 719
  • [26] Pluripotential mechanisms of cardioprotection with hmg-coa reductase inhibitor therapy
    Rosenson R.S.
    American Journal of Cardiovascular Drugs, 2001, 1 (6) : 411 - 420
  • [27] Photostability of pitavastatin-A novel HMG-CoA reductase inhibitor
    Grobelny, Pawel
    Viola, Giampietro
    Vedaldi, Daniela
    Dall'Acqua, Francesco
    Gliszczynska-Swiglo, Anna
    Mielcarek, Jadwiga
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2009, 50 (04) : 597 - 601
  • [28] Cerivastatin - A new HMG-CoA reductase inhibitor - In combination with the antacid Maalox(R): An investigation of the safety and pharmacokinetics
    Dietrich, H
    Ritter, W
    Wingender, W
    Unger, S
    Ochmann, K
    ATHEROSCLEROSIS, 1997, 130 : 101 - 101
  • [29] HMG-CoA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals
    Horimoto, H
    Nakai, Y
    Nakahara, K
    Nomura, Y
    Mieno, S
    Sasaki, S
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (04): : 440 - 445
  • [30] HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes
    van Harmelen, V
    Skurk, T
    Röhrig, K
    Hauner, H
    HORMONE AND METABOLIC RESEARCH, 2003, 35 (08) : 466 - 470
12345